Alnylam Pharmaceuticals, Inc. - ALNY STOCK NEWS

Alnylam Pharmaceuticals (ALNY) announced positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study met all primary and secondary endpoints, showing significant benefits in reducing mortality and cardiovascular events.

Key findings include:

• 28% reduction in primary composite of all-cause mortality and recurrent cardiovascular events in the overall population
• 36% reduction in all-cause mortality up to 42 months in the overall population
• 33% reduction in primary composite endpoint in the monotherapy population
• Significant improvements in disease progression measures and cardiac biomarkers

Vutrisiran demonstrated an encouraging safety profile consistent with previous studies. Alnylam plans to submit regulatory filings globally, starting later this year.

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its participation in two major investor conferences in September 2024. The company will present overviews at the Wells Fargo 2024 Healthcare Conference in Boston on September 4 at 9:30 am ET, and the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on the same day at 1:05 pm ET.

Investors and interested parties can access live audio webcasts of both presentations through the Investors section of Alnylam's website at www.alnylam.com/events. Replays will be made available within 48 hours after each event, allowing those unable to attend live to catch up on the company's latest updates and strategies.

Alnylam Pharmaceuticals (Nasdaq: ALNY) will present detailed results from the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy at the European Society of Cardiology (ESC) Congress 2024. The study met its primary endpoint, showing a significant reduction in all-cause mortality and recurrent cardiovascular events. Vutrisiran also demonstrated an acceptable safety profile.

The company will host an Investor Webcast on August 30, 2024, to discuss the results. Additionally, Alnylam will present findings from the KARDIA-2 Phase 2 study of zilebesiran for hypertension and new data from post-hoc analyses of the APOLLO-B Phase 3 and APOLLO-OLE studies of patisiran in ATTR amyloidosis with cardiomyopathy patients.

Alnylam Pharmaceuticals (ALNY) reported strong Q2 2024 results, with global net product revenues of $410 million, up 34% year-over-year. The growth was driven by the TTR business, which grew 37% annually. The company announced positive topline results from the HELIOS-B Phase 3 study of vutrisiran for ATTR cardiomyopathy, showing significant improvements in cardiovascular outcomes and mortality. Alnylam updated its 2024 financial guidance, increasing combined net product revenue guidance to $1,575-$1,650 million. The company achieved a GAAP operating income of $48.6 million and a non-GAAP operating income of $137.9 million for Q2 2024. Alnylam ended the quarter with $2.62 billion in cash and investments.

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its plan to report second quarter 2024 financial results on Thursday, August 1, 2024, before U.S. markets open. The company will host a conference call at 8:30 am ET on the same day, where management will provide a company update and discuss Q2 2024 results along with future expectations.

Investors can access a live audio webcast of the call on Alnylam's website in the Investors section. An archived version of the webcast will be available approximately two hours after the event.

Alnylam Pharmaceuticals reported positive topline results from its HELIOS-B Phase 3 study for vutrisiran, an RNAi therapeutic for ATTR amyloidosis with cardiomyopathy (ATTR-CM).

Statistically significant reductions in all-cause mortality and recurrent cardiovascular events were observed in both the overall population and monotherapy population. Specifically, the study showed a 28% reduction in the overall population and a 33% reduction in the monotherapy population.

Secondary endpoints also demonstrated significant improvements, including a 36% reduction in all-cause mortality in the overall population and a 35% reduction in the monotherapy population. Other key measures such as the 6-minute walk test, Kansas City Cardiomyopathy Questionnaire, and NYHA Class also showed clinical benefits.

The study confirmed vutrisiran's safety profile, with adverse events comparable between the vutrisiran and placebo groups. Alnylam plans to file a U.S. Supplemental New Drug Application and proceed with global regulatory submissions.

Alnylam Pharmaceuticals, Inc. issued its 2023 Corporate Responsibility Report, showcasing its commitment to environmental sustainability, patient access, and health equity. The report includes new data on environmental impact, expanded partnerships for diversity and inclusion in clinical trials, and the extension of the Alnylam Challengers global health equity initiative. Additionally, the report discloses employee demographic data and results of a pay equity analysis.

Alnylam Pharmaceuticals reported strong first quarter 2024 financial results with Global Net Product Revenues of $365 million, reflecting a 32% Year-Over-Year Growth. The company achieved positive results in the Zilebesiran Hypertension Program, initiated Phase 2 studies, and remains on track to report Topline Results from Vutrisiran's Phase 3 Study. Alnylam reiterated its 2024 Financial Guidance with expected combined Net Product Revenues of $1,400 million to $1,500 million.

Medison Pharma and Alnylam Pharmaceuticals have announced an expansion of their partnership to commercialize RNAi therapeutics in additional markets, including LATAM and APAC, to provide innovative therapies to patients across the globe. This partnership aims to accelerate access to Alnylam's life-saving therapies in multiple regions under one global alliance.